First-line treatment for advanced ccRCC...Sunitinib [I, A], pazopanib [I, A] and tivozanib [II, B; ESMO-MCBS v1.1 score: 1] are alternatives to PD-1 inhibitor-based first-line combinations when immune therapy is contraindicated or not available.
The NCCN Kidney Cancer Panel has listed pazopanib as a category 1 preferred option for first-line treatment of patients with favourable risk features with relapsed or medically unresectable clear cell stage IV RCC.